Prometheus Biosciences Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Prometheus Biosciences in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Prometheus Biosciences stock.
View analyst ratings for Prometheus Biosciences or view top-rated stocks.

Wall Street analysts have given Prometheus Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Prometheus Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Prometheus Biosciences, Inc. (NASDAQ:RXDX) announced its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.54) by $0.03.
View Prometheus Biosciences' earnings history.

4 Wall Street analysts have issued 1 year target prices for Prometheus Biosciences' stock. Their forecasts range from $25.00 to $40.00. On average, they expect Prometheus Biosciences' stock price to reach $32.25 in the next year. This suggests a possible upside of 51.6% from the stock's current price.
View analysts' price targets for Prometheus Biosciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Prometheus Biosciences include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Achilles Therapeutics plc American Depositary Shares (ACHL), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ) and Algernon Pharmaceuticals (AGNPF).
View all of RXDX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Prometheus Biosciences investors own include Cronos Group (CRON), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), SELLAS Life Sciences Group (SLS), Freeport-McMoRan (FCX), (KITE) (KITE), La Jolla Pharmaceutical (LJPC), Sorrento Therapeutics (SRNE), TransEnterix (TRXC) and TherapeuticsMD (TXMD).

(RXDX) raised $126 million in an initial public offering (IPO) on Friday, March 12th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. SVB Leerink, Credit Suisse, Stifel and Guggenheim Securities acted as the underwriters for the IPO.

Prometheus Biosciences trades on the NASDAQ under the ticker symbol "RXDX."

Prometheus Biosciences' quiet period expires on Wednesday, April 21st. Prometheus Biosciences had issued 10,000,000 shares in its IPO on March 12th. The total size of the offering was $190,000,000 based on an initial share price of $19.00. During Prometheus Biosciences' quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

One share of RXDX stock can currently be purchased for approximately $21.28.

Prometheus Biosciences employs 24 workers across the globe.

The official website for Prometheus Biosciences is ignyta.com.

Prometheus Biosciences is headquartered at 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States.

Prometheus Biosciences' mailing address is 4545 Towne Centre Ct, SAN DIEGO, CA 92121-1900, United States. The biopharmaceutical company can be reached via phone at +1-858-2555959.